Affiliation:
1. Tyumen Cardiology Research Center;
Tomsk National Research Medical Center
Abstract
Aim. To assess the relationship between the prolonged PR interval (≥200 ms) and the long-term survival of patients undergoing cardiac resynchronization therapy (CRT).Material and methods. A total of 85 patients (mean age — 55,1Ѓ}9,9 years; men — 81,2%) with NYHA class II-IV heart failure (HF) were examined. The mean follow-up was 34,0Ѓ}21,2 months. Patients with PR<200 ms (n=52) made up group I, with PR≥200 ms (n=33) — group II. Then the patients were divided into subgroups depending on the QRS duration: ≥150 ms (n=33 in group I and n=14 in group II, respectively) <150 ms (n=19 in group I and n=19 in group II, respectively).Results. In patients of group II, a history of myocardial infarction (MI) was more often registered (p=0,005), left ventricular ejection fraction (LVEF) was lower (p=0,032). In a multivariate analysis, MI (OR 3,217; CI 95% 1,188-8,712; p=0,022) and LVEF value (OR 0,869; CI 95% 0,780-0,968; p=0,011) had a significant relationship with the PR interval prolongation (≥200 ms). The survival of patients of group I was 59,6%, group II — 18,2% (Log-rank test p<0,001). According to Cox regression model, the initial left ventricle end-systolic volume (OR 1,012; 95% CI 1,006-1,017; p<0,001), inferior wall MI (OR 1,690; 95% CI 1,131-2,527; p=0,011) and PR interval ≥200 ms (OR 2,179; 95% CI 1,213–3,915; p=0,009) were associated with long-term mortality. In patients with PR≥200 ms, survival rate was low, regardless of the QRS duration (21,4% in patients with QRS≥150 ms, 15,8% in patients with QRS<150 ms; Log-rank test p=0,698) In patients with PR<200 ms, the survival rate of patients with QRS≥150 ms was 72,7%, and for patients with QRS<150 ms — 36,8% (Log-rank test p=0,031).Conclusion. In HF patients, PR interval prolongation (≥200 ms) is associated with long-term mortality increase. The highest survival rates were observed in patients with PR<200 ms and QRS≥150 ms. In patients with QRS≥150 ms, the presence of PR≥200 ms should be considered as an additional criterion for CRT.
Subject
Cardiology and Cardiovascular Medicine
Reference15 articles.
1. Mareev V.Ju., Ageev F.T., Arutjunov G.P., Koroteev A.V., Mareev Ju.V., Ovchinnikov A.G., Belenkov Ju.N., Vasjuk Ju.A., Galjavich A.S., Garganeeva A.A., Giljarevskij S.R., Glezer M.G., Koziolova N.A., Koc Ja.I., Lopatin Ju.M., Martynov A.I. (prezident RNMOT), Moiseev V.S., Revishvili A.Sh., Sitnikova M.Ju., Skibickij V.V., Sokolov E.I., Storozhakov G.I., Fomin I.V., Chesnikova A.I., Shljahto E.V. (prezident RKO) National guidelines OSSN,RCS and RNMOT for diagnosis and treatment of CHF (fourth revision). Journal of heart failure. 2013; 14: 7(81). (In Rus).
2. Cleland J.G.F., Abraham W.T., Linde C. et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. European heart journal. 2013; 34 (46):3547-3556.
3. Poole J.E., Singh J.P., Birgersdotter-Green U. QRS Duration or QRS Morphology What Really Matters in Cardiac Resynchronization Therapy? Journal of the American College of Cardiology. 2016; 67(9), 1104-1117. https://doi.org/10.1016/j.jacc.2015.12.039
4. Nikolaidou T, Ghosh J.M., Clark A.L. Outcomes related to first-degree atrioventricular block and therapeutic implications in patients with heart failure. JACC: Clinical Electrophysiology. 2016 Apr 1;2(2):181-92. doi: 10.1016/j.jacep.2016.02.012.
5. Gervais R., Leclercq C., Shankar A., Jacobs S., Eiskjaer H., Johannessen A., Freemantle N., Cleland J.G., Tavazzi L., Daubert C.; CARE-HF investigators. Surface electrocardiogram to predict outcome in candidates for cardiac resynchronization therapy: a subanalysis of the CARE-HF trial. Eur J Heart Fail 2009;11:699–705. doi: 10.1093/eurjhf/hfp074.